ATM, CHEK2, and PTEN Genes in Breast Cancer
Jane E. Churpek, MD, medical oncologist, hematologist, The University of Chicago, discusses the ATM, CHEK2, and PTEN genes in breast cancer.
Jane E. Churpek, MD, medical oncologist, hematologist, The University of Chicago, discusses the ATM, CHEK2, and PTEN genes in breast cancer.
It is known, Churpek says, that ATM and CHEK2 are considered moderate penetrants breast cancer susceptibility genes and increase the lifetime risk of disease by two- to threefold. PTEN also has known risks for breast cancer, colon cancer, endometrial cancer, and thyroid cancer.
Clinical Pearls
The panel on the study also found a woman with two bad copies of a CHEK2 mutation, which further increased her risk. In broad screenings, Churpek says that these unique situations can be identified and give more meaning to what is already known about specific gene mutations.
- ATM and CHEK2 are moderate penetrants breast cancer susceptibility genes and increase the lifetime risk of disease by two- to threefold
- PTEN also has known risks for breast cancer, colon cancer, endometrial cancer, and thyroid cancer
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
